<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

Multiple Myeloma Research Benefits from Living Model SLR: A Case Study

WWR 7_banner

The speed of scientific discovery has been outpacing the ability of researchers to accumulate and integrate constantly evolving new insights into systematic literature reviews (SLRs). This gets compounded by obstacles to accessing the newest publications.

For one pharmaceutical company looking to evaluate the potential impact of surrogate endpoints on long-term clinical outcomes in multiple myeloma, an SLR was needed in just two months for the research to support reimbursement submissions. Was it possible?

There are several distinct subpopulations of multiple myeloma that had to be taken into consideration when preparing the SLR. This amounted to 300 relevant published studies that a thorough SLR had to take into account, with an average of 50 abstracts published per month. At that rate, there might have been dozens more published in that two-month window.

To accomplish this goal, our experts used LiveSLR® – a Cytel software that leverages the power and scope of an AI scan combined with the judgement of an industry-leading evidence generation team – and an existing oncology library of up-to-date interventional, RWE, quality of life, and economic studies.

The outcome was an SLR that met established HTA submission standards.

By using LiveSLR, the evidence for the project was available quickly and reflected the most recent scientific findings.

Want to learn more? Download our complimentary position paper, “LiveSLR: The Urgent Need to Demonstrate Value in Real Time,” below:


Download Publication


The Winter Weekends Reads series features complimentary publications on a variety of topics on clinical trial design and data science. Subscribe to our weekly newsletter below and never miss a post!


Read more from Perspectives on Enquiry & Evidence:

Sorry no results please clear the filters and try again

Demystifying Synthetic Control Arms

Last week, Cytel Director & Research Principal Louis Dron discussed new FDA guidance on the design and conduct of...
Read more

Simulation-Guided Design Is Reshaping Clinical Trial Strategy

You may have heard that our clinical trial strategy platform Solara® won the Fierce Life Sciences award for Technology...
Read more

To Adapt or Not to Adapt? A Decision Framework

Should your clinical trial be adaptive? Trials that include a prospectively planned modification based on an interim...
Read more

If you'd like updates on our blog posts, sign up for email updates below.

contact iconSubscribe back to top